Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs AT&T Inc. — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while AT&T Inc. trades at $23.39 (market cap $157.95B). The key difference: AT&T Inc. is far larger — about 17.8× Kymera Therapeutics Inc. Common Stock's market cap, and AT&T Inc. pays a 4.82% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and AT&T Inc. for 118 Days on average.
| KYMR | T | |
|---|---|---|
Market Cap | $8.88B | $157.95B |
Volume | 1,028,790 | 40,269,473 |
Sector | Health | Media |
52-Week High | $127.31 | $29.10 |
52-Week Low | $55.80 | $20.49 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $8.27B | $303.27B |
Dividend Yield | — | 4.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
AT&T (T) trades at $22.86, up 1.65% with strong fundamentals including a P/E of 7.61 and net income margin of 16.94%. The stock shows consistent earnings beats and positive cash flow trends, though technical indicators signal bearish momentum. Recent developments include a $3 billion fiber deal with Corning and participation in a satellite connectivity joint venture with major carriers.
The stock appears undervalued with analyst consensus target of $27.39 offering 20% upside potential. Key risks include heavy debt load and competitive pressures, while opportunities lie in fiber expansion and AI infrastructure growth. Dividend sustainability remains a focus area for income investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
